The Super Network of Premier Research Sites

Who is hyperCORE International?


hyperCORE International is a super network of highly experienced and awarded clinical trial sites working together to accelerate and advance clinical research. Each member operates as an independent company but integrates common functions to streamline business and clinical operations through harmonization and sharing of best practices. Currently, hyperCORE International is comprised of 11 alliance partners with over 100 sites spanning 2 continents and 5 countries.

hyperCORE International Partners


hyperCORE International brings together the clinical research industry’s most respected and advanced clinical trial companies, facilitating a level of collaboration unmatched in scope – its sole purpose is to advance the efficiency of clinical trials and ultimately improve the health and wellbeing of diverse populations across the globe. The collaboration between hyperCORE’s alliance partner companies is reflective of an industry demand for more professionalized and efficient models for the delivery of clinical trials. Each alliance partner is thoroughly vetted prior to acceptance, reflecting hyperCORE’s values in superior quality, experience, efficiency and industry leadership.

When you need the Premier Global Network

hyperCORE International is strategically prepared to assist you through COVID-19 and beyond.

hyperCORE International Executives


Integrated by high-quality professionals, with more than 30 years of experience in clinical research, driving by the mission to improve and innovate healthcare.

Karri Venn
Chief Executive Officer
Mark Lacy
Chairman of the Board
Dr. Roberto Aguirre
Chief Medical Officer
Dr. Jeff Kingsley
Chief Operational Officer

“hyperCORE International is one of the premier integrated research networks in the industry and I am honored to be voted in as CEO from my peers to take on the leadership of this amazing team. In a time of uncertainty, research has a vital role in finding a solution to this pandemic and the future of research sites is changing rapidly of which hyperCORE International is poised to be leading”

- Karri Venn, CEO
Play Video
Total Available Patient for Recruitment

15,000,000+

Total Sites: 2 Continents, 5 Countries

100+

Total Principal Investigators

140+

Total Therapeutic Areas

35+

Total Trials Conducted

7,000+

Total Patients Randomized

140,000+